-
Attention Biotech Investors, Here's Your PDUFA Primer For October
Thursday, September 28, 2017 - 10:51am | 1961Read More...The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In September, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has lost 0.44...
-
Market Wrap For December 31: Markets End The Year On A Positive Note
Tuesday, December 31, 2013 - 5:29pm | 1198Read More...As markets completed its final trading day of 2013, investors and traders can look back at what turned out to be a spectacular year for equities. U.S. stocks had its best year in over a decade fueled by an improving economy and the Fed's easy money policies. Commodities on the other hand have...
-
J.P. Morgan Downgrades AMAG To Neutral
Wednesday, May 4, 2011 - 9:13am | 223Read More...According to J.P. Morgan, AMAG Pharmaceuticals (NASDAQ: AMAG) reported a 1Q loss per share of ($1.05) versus consensus of ($0.99) and the estimate of ($1.04). J.P. Morgan said that the downside was driven by lower Feraheme sales of $10.9M (JPMe: $14.4M; cons: $14M), partially offset by lower opex...
-
JP Morgan Downgrades AMAG Pharmaceuticals To Neutral, PT To $20
Wednesday, May 4, 2011 - 6:39am | 28Read More...JP Morgan has downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Overweight to Neutral and has lowered the price target from $28 to $20.
-
Morgan Stanley Initiates EW Rating For AMAG
Friday, March 18, 2011 - 8:05am | 110Read More...Morgan Stanley has issued an Equal-Weight Rating and $17 PT for AMAG Pharmaceuticals (NASDAQ: AMAG). Morgan Stanley writes, "We are assuming coverage of AMAG with an EW rating and $17 PT. Feraheme, an intravenous iron (IVFe) approved in ‘09 to treat iron deficiency anemia (IDA) associated with...
-
Morgan Stanley Initiates EW Rating For AMAG
Friday, March 18, 2011 - 8:03am | 110Read More...Morgan Stanley has issued an Equal-Weight Rating and $17 PT for AMAG Pharmaceuticals (NASDAQ: AMAG). Morgan Stanley writes, "We are assuming coverage of AMAG with an EW rating and $17 PT. Feraheme, an intravenous iron (IVFe) approved in ‘09 to treat iron deficiency anemia (IDA) associated with...
-
Jefferies Maintains UW Rating On AMAG
Tuesday, January 11, 2011 - 9:21am | 65Read More...Jefferies is maintaining its rating on AMAG Pharmaceuticals (NASDAQ: AMAG). “We view below-consensus 2011 Feraheme sales guidance as too optimistic and maintain our below-guidance sales estimate,” Jefferies writes. “We remain bearish on Feraheme potential and keep our peak annual sales potential at...
-
AMAG 2011 Guidance Disappoints, J.P. Morgan Reports
Monday, January 10, 2011 - 11:33am | 97Read More...AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) has provided an update and pre-announces 4Q10 Feraheme revenues of $14.5- 15.5M inline with expectations, J.P. Morgan reports. “The company also provided 2011 Feraheme revenue guidance of $55-60M, which was somewhat disappointing (cons: $74M and JPMe: $94M...
-
Feraheme 4Q Estimates Higher Than Citigroup's On AMAG
Monday, January 10, 2011 - 10:13am | 174Read More...Citigroup has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and believes that 2011 Revenue Guidance provides some hope despite high expectations. In the report, Citigroup writes "Today, AMAG pre-announced Q4:10 Feraheme sales and provided 2011 guidance. Feraheme Q4 sales of $14...
-
Jefferies Sees ~$100M Sales Potential In 2011 For AMAG
Monday, January 10, 2011 - 10:10am | 197Read More...Jefferies & Company has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has decided that current sales guidance appears a bit aggressive. In the report, Jefferies writes "Contrast to strong IMS sales data, 4Q Feraheme sales came in line with expectations (~flat q/q). As...
-
AMAG Pharmaceuticals (AMAG) Shares Fall Nearly 7%
Monday, March 1, 2010 - 12:21pm | 89Read More...Shares of AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) tumbled 6% during morning trading after the company produced financial results that failed to impress Wall Street. The bio-pharmaceutical company reported a net loss of $18.4 million, or $1.07 per share, versus a net loss of $21.8 million, or $1....
